Table of Contents
  Encyclosphere.org ENCYCLOREADER
  supported by EncyclosphereKSF

Sangamo Therapeutics

Topic: Company

 From HandWiki - Reading time: 4 min
Short description: American cell and gene therapy company
Sangamo Therapeutics
TypePublic
NASDAQ: SGMO
Russell 2000 Index component
IndustryBiotechnology
Founded1995
Headquarters
Brisbane, California, US
Key people
Sandy Macrae (CEO)
Edward Rebar (CTO)
RevenueIncrease $111.3 million[1] (2022)
Increase -$201.281 million[1] (2022)
Increase $192.3 million[1] (2022)
Total assetsDecrease $562.5 million[1] (2022)
Total equityDecrease $294.958 million[1] (2022)
Number of employees
354
Websitesangamo.com
Footnotes / references
[1]
President and CEO Sandy Macrae in 2018

Sangamo Therapeutics, Inc. (previously known as Sangamo Biosciences, Inc.) is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.[2]

History

The company was founded in 1995 in Richmond, California.[3] It was originally known as Sangamo Biosciences, Inc. before changing names in 2017. In September 2018, it had 182 employees.[3] Sandy Macrae is the president.[4] In 2018, Edward Rebar became the senior vice president and chief technology officer of Sangamo.[5]

Research

Sangamo applies technology to treat haemophilia B and lysosomal storage diseases including mucopolysaccharidosis type I (Hurler Syndrome) and mucopolysaccharidosis type II (Hunter Syndrome). The FDA granted Sangamo fast track designation for SB-525, a gene therapy candidate for haemophilia A. In its partnership with Pfizer in 2017,[6] Sangamo uses Bioverativ in hemoglobinopathies such as beta thalassemia and sickle cell disease.[2] It is also developing zinc finger gene editing technology.[7]

In February 2019, medical scientists, working with Sangamo Therapeutics, announced the first ever "in body" human gene editing therapy to permanently alter DNA - in a patient with Hunter syndrome.[8] (As of February 2019) clinical trials by Sangamo involving gene editing using zinc finger nuclease were ongoing.[9]

Clinical trials

Sangamo's programs are a mix of wholly owned and partnered; major partners include Pfizer, Biogen, Sanofi, Takeda, and Kite (a Gilead company).[10][2][11][12]

As of 2020 Sangamo had the following clinical trials underway in the US:

In February 2023, Sangamo Therapeutics announced that it would stop the late-stage development for the Phase 1/2 PRECIZN-1 study of BIVV003 its sickle cell drug.[20]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results". Sangamo. 22 February 2023. https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-reports-recent-business-highlights-and-5. 
  2. ↑ 2.0 2.1 2.2 McConaghie, Andrew (2017-05-17). "Sangamo and new gene therapy partner Pfizer lifted by FDA fast track" (in en-GB). Pharmaphorum. https://pharmaphorum.com/news/sangamo-new-gene-therapy-partner-pfizer-lifted-fda-fast-track/. 
  3. ↑ 3.0 3.1 "Sangamo Therapeutics Inc. (SGMO) Moves Higher on Volume Spike for September 04" (in en-US). Equities. 2018-09-08. https://www.equities.com/news/sangamo-therapeutics-inc-sgmo-moves-higher-on-volume-spike-for-september-04. 
  4. ↑ Ledford, Heidi (2018-09-05). "First test of in-body gene editing shows promise" (in EN). Nature. doi:10.1038/d41586-018-06195-6. ISSN 0028-0836. http://www.nature.com/articles/d41586-018-06195-6. 
  5. ↑ "Sangamo Therapeutics appoints Edward Rebar as senior vice president" (in en). Richmond, California. 2018-07-16. http://www.poandpo.com/who-is-promoted/sangamo-therapeutics-appoints-edward-rebar-as-senior-vice-president--1672018988/. 
  6. ↑ "SANGAMO THERAPEUTICS AND PFIZER ANNOUNCE COLLABORATION FOR HEMOPHILIA A GENE THERAPY | Pfizer". https://www.pfizer.com/news/press-release/press-release-detail/sangamo_therapeutics_and_pfizer_announce_collaboration_for_hemophilia_a_gene_therapy. 
  7. ↑ Renauer, Cory (2018-09-06). "Sangamo's Zinc Fingers Fail Again. Time to Walk Away?" (in en). The Motley Fool. https://www.fool.com/investing/2018/09/06/sangamos-zinc-fingers-fail-again-time-to-walk-away.aspx. 
  8. ↑ Marchione, Marilyn (7 February 2019). "Tests suggest scientists achieved 1st 'in body' gene editing". AP News. https://www.apnews.com/d728f86d70d94ce68dd4fedffe58d03f. 
  9. ↑ Staff (2 February 2019). "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II". U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT03041324. 
  10. ↑ Reuters Editorial. "SGMO.OQ - Sangamo Therapeutics Inc Profile | Reuters" (in en). https://www.reuters.com/companies/SGMO.OQ. 
  11. ↑ "Sangamo shares jump on Pfizer, Sanofi (and its own) gene, cell therapy updates" (in en). https://www.fiercebiotech.com/biotech/sangamo-shares-jump-pfizer-sanofi-and-its-own-gene-and-cell-therapy-updates. 
  12. ↑ "Exciting new Huntingtin lowering tool described - HDBuzz - Huntington's disease research news.". https://en.hdbuzz.net/275. 
  13. ↑ "A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT03432364. 
  14. ↑ "Dose-Ranging Study of ST-920, a rAAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT04046224. 
  15. ↑ "A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT03653247. 
  16. ↑ "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT03041324. 
  17. ↑ "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT02702115. 
  18. ↑ "Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT03061201. 
  19. ↑ "Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT02695160. 
  20. ↑ "Sangamo shelves sickle cell therapy, joining rivals forced to rethink development plans" (in en). Fierce Biotech. 2023-02-23. https://www.fiercebiotech.com/biotech/sangamo-shelves-sickle-cell-therapy-joining-rivals-forced-rethink-development-plans-disease. 

External links

[ ⚑ ] 37°40′36″N 122°23′03″W / 37.67669°N 122.38421°W / 37.67669; -122.38421




Retrieved from "https://handwiki.org/wiki/index.php?title=Company:Sangamo_Therapeutics&oldid=3473969"
Licensed under CC BY-SA 3.0 | Source: https://handwiki.org/wiki/Company:Sangamo_Therapeutics
8 views | Status: cached on July 19 2024 22:39:42
↧ Download this article as ZWI file
Encyclosphere.org EncycloReader is supported by the EncyclosphereKSF